Finanzas de Olema Pharmaceuticals Inc (OLMA)OLMAOlema Pharmaceuticals Inc

Evaluating the bottom line, Olema Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -52.74%, provide a clear picture of how effectively OLMA converts its operational activities into shareholder value.

In the context of the broader market, OLMA competes directly with industry leaders such as PBYI and ACRS. With a market capitalization of $560.86M, it holds a leading position in the sector. When comparing efficiency, OLMA's gross margin of N/A stands against PBYI's 77.92% and ACRS's 10.80%. Such benchmarking helps identify whether Olema Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

The financial performance shows consistent losses, with net income reaching -63.2 million in Q2 2026 and a negative ROE of -52.74%.